Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

The Lancet Oncology
C Le TourneauSHIVA investigators

Abstract

Molecularly targeted agents have been reported to have anti-tumour activity for patients whose tumours harbour the matching molecular alteration. These results have led to increased off-label use of molecularly targeted agents on the basis of identified molecular alterations. We assessed the efficacy of several molecularly targeted agents marketed in France, which were chosen on the basis of tumour molecular profiling but used outside their indications, in patients with advanced cancer for whom standard-of-care therapy had failed. The open-label, randomised, controlled phase 2 SHIVA trial was done at eight French academic centres. We included adult patients with any kind of metastatic solid tumour refractory to standard of care, provided they had an Eastern Cooperative Oncology Group performance status of 0 or 1, disease that was accessible for a biopsy or resection of a metastatic site, and at least one measurable lesion. The molecular profile of each patient's tumour was established with a mandatory biopsy of a metastatic tumour and large-scale genomic testing. We only included patients for whom a molecular alteration was identified within one of three molecular pathways (hormone receptor, PI3K/AKT/mTOR, RAF/MEK), which could...Continue Reading

References

Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Mar 5, 2005·The New England Journal of Medicine·Elizabeth HorstmannChristine Grady
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Charles SoriaHassane Izzedine
Apr 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hendrik-Tobias ArkenauStan Kaye
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Jul 29, 2010·The Journal of Clinical Investigation·Federica Di NicolantonioAlberto Bardelli
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel D Von HoffRobert Penny
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Feb 24, 2012·The New England Journal of Medicine·Jeffrey A SosmanAntoni Ribas
Jun 8, 2012·The New England Journal of Medicine·Aleksandar SekulicAxel Hauschild
Sep 12, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Apostolia-Maria TsimberidouRazelle Kurzrock
Feb 21, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Monika K Krzyzanowska
Apr 20, 2013·Journal of Oncology Practice·Stacy W GrayJane C Weeks
Jun 4, 2013·The New England Journal of Medicine·Alice T ShawPasi A Jänne
Sep 28, 2013·Nature Genetics·Giovanni CirielloChris Sander
Mar 26, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stacy W GrayJane C Weeks
Jul 6, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Apostolia-Maria TsimberidouDonald Berry
Sep 30, 2014·The New England Journal of Medicine·James LarkinAntoni Ribas

❮ Previous
Next ❯

Citations

Feb 3, 2016·Future Oncology·Shuang Qin Zhang, Daniel V T Catenacci
Mar 13, 2016·Seminars in Oncology·Tito Fojo
Feb 10, 2016·Cancer Metastasis Reviews·Jason K SicklickRazelle Kurzrock
Feb 13, 2016·The Lancet Oncology·Rakesh JalaliRajendra Badwe
Feb 24, 2016·Progress in Cardiovascular Diseases·Michael J Joyner
Feb 27, 2016·Cancer Letters·Sameh MikhailTanios Bekaii-Saab
Jan 19, 2016·Molecular Oncology·Leticia De Mattos-Arruda, Carlos Caldas
Feb 28, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Christopher D HartAngelo Di Leo
Dec 19, 2015·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Alexandre VivotRaphaël Porcher
Dec 19, 2015·The Lancet Oncology·Apostolia M Tsimberidou, Razelle Kurzrock
Dec 19, 2015·The Lancet Oncology·Christophe Le TourneauMaud Kamal
Mar 27, 2016·Gynecologic Oncology·Lorna Rodriguez-RodriguezShridar Ganesan
Nov 26, 2015·Journal of the National Cancer Institute·Christophe Le TourneauIvan Bièche
Apr 6, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J OvermanS Kopetz
Sep 8, 2015·The Lancet Oncology·Daniel V T Catenacci
May 21, 2016·Frontiers in Oncology·Elise C Kohn, S Percy Ivy
May 10, 2016·Clinical Therapeutics·Jon ZugazagoitiaLuis Paz-Ares
Jun 2, 2016·Expert Opinion on Drug Metabolism & Toxicology·Nicholas Li-Xun SynSoo-Chin Lee
Jun 3, 2016·Expert Review of Molecular Diagnostics·Loren Joseph
Jun 29, 2016·Nature Reviews. Clinical Oncology·Nicolas AndréEddy Pasquier
Oct 28, 2016·Annals of the New York Academy of Sciences·Yongjing LiuXiaoxin Luke Chen
Aug 2, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Barbara C WorstOlaf Witt
Aug 2, 2016·Trends in Genetics : TIG·Geoff MacintyreJames D Brenton
Aug 9, 2016·Leukemia Research·Vinay Prasad, Robert Peter Gale
Nov 2, 2016·Expert Review of Molecular Diagnostics·Eva C Winkler, Stefan Wiemann
Jun 16, 2016·Future Oncology·Jonathan M Loree, Winson Y Cheung
Sep 18, 2016·Critical Reviews in Oncology/hematology·Marcello Maugeri-SaccàRuggero De Maria
May 6, 2016·Journal of Cellular Biochemistry·Mary D ChamberlinTodd W Miller
Dec 19, 2015·The Lancet Oncology·Glen J Weiss
Dec 19, 2015·The Lancet Oncology·Andrew W Hahn, Mike G Martin
Feb 13, 2016·The Lancet Oncology·Vinay PrasadMichael Brada
Sep 30, 2016·The New England Journal of Medicine·Ian F Tannock, John A Hickman
Oct 5, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Vinay Prasad
Nov 3, 2016·Nature Reviews. Clinical Oncology·Christophe Le Tourneau, Razelle Kurzrock
Oct 18, 2016·Pediatric Blood & Cancer·Rajen J ModyArul M Chinnaiyan
Nov 10, 2016·Expert Review of Molecular Diagnostics·Rebecca A PrevisShannon N Westin
Nov 30, 2016·Pediatric Blood & Cancer·Thomas PincezGudrun Schleiermacher
Dec 7, 2016·PLoS Medicine·James T Topham, Marco A Marra
Jan 6, 2017·International Journal of Molecular Sciences·Angela TossLaura Cortesi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

© 2021 Meta ULC. All rights reserved